Apontis Pharma AG/€APPH
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Apontis Pharma AG
Apontis Pharma AG, headquartered in Monheim am Rhein, Germany, specializes in the development and marketing of pharmaceutical products, with a primary focus on Single Pills that combine multiple active ingredients into a single dosage form. ([apontis-pharma.de](https://apontis-pharma.de/en/business-development?utm_source=openai)) The company's portfolio predominantly addresses cardiovascular conditions such as hypertension and hyperlipidemia, as well as respiratory diseases and diabetes. ([stockanalysis.com](https://stockanalysis.com/quote/etr/APPH/company/?utm_source=openai)) Founded in 1946 as Schwarz Pharma, the company underwent several ownership changes before adopting its current name in 2019. ([apontis-pharma.de](https://apontis-pharma.de/en/history?utm_source=openai)) Apontis Pharma has established strategic partnerships, including collaborations with Midas Pharma and AstraZeneca, to develop and promote Single Pills with pan-European intellectual property rights. ([midas-pharma.com](https://www.midas-pharma.com/en/latest-activities/midas-pharma-and-apontis-pharma-announce-development-partnership/?utm_source=openai), [pharmiweb.com](https://www.pharmiweb.com/press-release/2022-03-08/apontis-pharma-and-astrazeneca-extend-strategic-sales-cooperation?utm_source=openai)) The company's strategic focus on Single Pills aims to enhance patient compliance and therapeutic outcomes by simplifying medication regimens. ([apontis-pharma.de](https://apontis-pharma.de/en/business-development?utm_source=openai))
Ticker
€APPH
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
137
ISIN
DE000A3CMGM5
Website
APPH Metrics
BasicAdvanced
€91M
120.82
€0.09
1.24
-
Price and volume
Market cap
€91M
Beta
1.24
52-week high
€12.35
52-week low
€6.30
Average daily volume
1.6K
Financial strength
Current ratio
2.486
Quick ratio
1.702
Interest coverage (TTM)
10.39%
Profitability
EBITDA (TTM)
3.434
Gross margin (TTM)
57.16%
Net profit margin (TTM)
1.55%
Operating margin (TTM)
2.46%
Effective tax rate (TTM)
33.04%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
1.47%
Return on equity (TTM)
2.46%
Valuation
Price to earnings (TTM)
120.822
Price to revenue (TTM)
1.879
Price to book
2.93
Price to tangible book (TTM)
4.79
Price to free cash flow (TTM)
-17.371
Free cash flow yield (TTM)
-5.76%
Free cash flow per share (TTM)
-62.92%
Growth
Revenue change (TTM)
31.12%
Earnings per share change (TTM)
-106.67%
3-year revenue growth (CAGR)
-1.80%
3-year earnings per share growth (CAGR)
1.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apontis Pharma AG stock?
Apontis Pharma AG (APPH) has a market cap of €91M as of July 01, 2025.
What is the P/E ratio for Apontis Pharma AG stock?
The price to earnings (P/E) ratio for Apontis Pharma AG (APPH) stock is 120.82 as of July 01, 2025.
Does Apontis Pharma AG stock pay dividends?
No, Apontis Pharma AG (APPH) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Apontis Pharma AG dividend payment date?
Apontis Pharma AG (APPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Apontis Pharma AG?
Apontis Pharma AG (APPH) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.